Investing.com -- InfuSystem Holdings Inc (NYSE American:INFU) stock rose 2% in after-hours trading on Wednesday after the company announced that two of its electronic infusion pumps used in pain management have been added to the Centers for Medicare and Medicaid Services (CMS) list for separate payment under the Non-Opioids Prevent Addiction in the Nation (NOPAIN) Act.
The CADD-Solis™ pump manufactured by ICU Medical, Inc. and Eitan Medical’s Sapphire™ pump will now be eligible for separate Medicare reimbursement when used in Hospital Outpatient and Ambulatory Surgical Center settings. This change, effective January 1, 2026, could potentially boost InfuSystem’s Pain Management business by encouraging healthcare providers to add the company’s services to their formularies.
CMS has set a payment limitation of up to $1,997.16 for these pumps and assigned unique HCPCS codes (C9815 for CADD-Solis™ and C9811 for Sapphire™) for claim submissions. The NOPAIN Act, which was passed as part of the Consolidated Appropriation Act of 2023, mandates separate payment for qualified non-opioid treatments through December 31, 2027.
"We are very glad to see that CMS has expanded upon its initial decision from last year and acknowledged that electronic infusion pumps such as the CADD-Solis™ and the Sapphire™ are effective non-opioid options for reducing opioid use after surgery," said Carrie Lachance, InfuSystem CEO.
While the company views this development as a potential catalyst for growth, management remains cautious about its immediate impact. "Our forward outlook will continue to be tempered until we gain further understanding surrounding the requirements for reimbursement and until we see adoption by our current and potential customers," Lachance added.
The initiative is part of CMS’s broader strategy to combat the opioid crisis by promoting safer pain management alternatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.








